Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib vs Biologics or Tofacitinib in RA
NCT03755466Phase 2Unknown
- Sponsor
- Shinshu University
- Start
- Nov 2018
- Primary completion
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of baricitinib in rheumatoid arthritis (RA) (3 arms), sponsored by Shinshu University. Primary endpoints: Disease Activity Score 28-CRP at 1 year and Adverse Events at 1 year. Status: unknown.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03755466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03755466.